SAN DIEGO, CA – October 15, 2021 – The National Center for Advancing Translational Sciences (NCATS) has chosen a multidisciplinary team of computational scientists and experimentalists from AnaBios and the Georgia Institute of Technology as one of four groups to progress to the next round in the 2020 NCATS ASPIRE Reduction-to-Practice Challenge. The winning project of the AnaBios-Georgia Tech team is entitled, “Development of a Comprehensive Integrated Platform for Translational Innovation in Pain, Opioid Abuse Disorder and Overdose.”

Led by principal investigator Jeffrey Skolnick, Ph.D., from Georgia Tech and co-investigator Andre Ghetti, Ph.D., Chief Executive Officer of AnaBios, the team has been conducting an in silico screen aimed at the identification of novel lead molecules to treat chronic pain without the risk of addiction. Virtual screening hits are being validated with AnaBios’ in vitro human primary neuron preparations, which will establish the potential of the compounds and the predictive ability of the combined approach.

The team also includes Nicole Jung, Ph.D., from the Karlsruhe Institute of Technology in Germany, and Hongyi Zhou, Ph.D., from the Georgia Institute of Technology.

“We are pleased to progress to the next round of the NCATS ASPIRE Challenge and are honored by the NIH’s recognition of our efforts to help solve the national opioid public health crisis,” said Dr. Ghetti.

The NIH launched the HEAL Initiative in April 2018 to improve prevention and treatment strategies for opioid misuse and addiction and enhance pain management (https://heal.nih.gov/). The NIH HEAL Initiative aims to improve treatments for chronic pain, curb the rates of opioid use disorder and overdose and achieve long-term recovery from opioid addiction.

Click here to learn more about this collaborative research from AnaBios and Georgia Tech University scientists.

About AnaBios

Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies. AnaBios primarily focuses on areas of high, unmet medical need, including cardiac disease, pain and itch. In addition to working with Fortune 500 biotech companies, CROs and academia, AnaBios drives an internal drug discovery platform via in-licensed programs from partners in the pharmaceutical industry. For more information about AnaBios, visit http://www.anabios.com.

 

 

###